United Kingdom Fragment-Based Drug Discovery Market Insight
The United Kingdom Fragment-Based Drug Discovery Market is growing at an 11.98% CAGR, driven by rising demand for efficient drug development, increasing adoption of structure-based design, and strong research support from organizations such as the Medical Research Council, with innovations in screening technologies improving lead optimization and success rates
United Kingdom Fragment-Based Drug Discovery Market Insights Forecasts to 2035
- The United Kingdom Fragment-Based Drug Discovery Market Size Was Estimated at USD 40.4 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 11.98% from 2025 to 2035
- The United Kingdom Fragment-Based Drug Discovery Market Size is Expected to Reach USD 125.3 Million by 2035
Notable Insights for United Kingdom Fragment-Based Drug Discovery Market
- By technology, X-ray crystallography and NMR spectroscopy dominated, accounting for approximately 55–60% share in 2024, driven by precise structural insights.
- By application, oncology and infectious diseases held approximately 60–65% share, due to high unmet medical needs and active research pipelines.
- Approximately 35–40% of early-stage drug discovery programs in the UK utilize fragment-based approaches, reflecting increasing adoption in lead identification.
- Around 65–70% of pharmaceutical companies prefer fragment-based methods for higher efficiency, reduced attrition rates, and cost-effective drug discovery processes.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Fragment-Based Drug Discovery Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Fragment-Based Drug Discovery Market
- Astex Pharmaceuticals
- Charles River Laboratories
- Evotec
- Domainex
- Sygnature Discovery
- WuXi AppTec
- Thermo Fisher Scientific
- Albany Molecular Research Inc
- Others
Recent Developments:
- In December 2024: Cancer Research Horizons partnered with Diamond Light Source to expand fragment-based drug discovery using the XChem platform, improving screening throughput and data analysis for cancer therapies.
- In July 2023: Domainex expanded biophysical capabilities with new high-throughput screening technologies, enhancing fragment-based drug discovery efficiency and accelerating molecular interaction analysis for complex therapeutic targets.
Market Segmentation:
United Kingdom Fragment-Based Drug Discovery Market, By Technology
- X-ray Crystallography
- Nuclear Magnetic Resonance (NMR)
- Surface Plasmon Resonance (SPR)
- Computational Screening
- Others
United Kingdom Fragment-Based Drug Discovery Market, By Application
- Oncology
- Infectious Diseases
- Neurological Disorders
- Cardiovascular Diseases
- Others
United Kingdom Fragment-Based Drug Discovery Market, By End User
- Pharmaceutical Companies
- Biotechnology Companie
- Academic & Research Institutes
United Kingdom Fragment-Based Drug Discovery Market, By Workflow Stage
- Fragment Screening
- Fragment Optimization
- Lead Generation
Expert Views:
The UK Fragment-Based Drug Discovery Market is expected to grow steadily due to increasing demand for non-invasive, patient-friendly drug administration methods and rising chronic disease burden. Experts emphasize that transdermal patches will remain dominant, supported by NHS preference for improving adherence and reducing systemic side effects. Advancements in microneedle technologies and biologic drug delivery are anticipated to expand therapeutic applications. Additionally, ongoing innovation in adhesive formulations and controlled-release mechanisms will significantly enhance treatment efficiency and drive market expansion through 2035.